• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura Medical

Nemaura Medical wins regulatory approval for non-invasive glucose sensor in the Middle East

August 17, 2023 By Sean Whooley

Nemaura Medical sugarBEAT continuous glucose monitor CGM

Nemaura Medical (Nasdaq:NMRD) announced today that it received Saudi Food and Drug Authority (SFDA) approval for its sugarBEAT sensor. The company develops daily, non-invasive, disposable, wearable glucose sensors. It also offers digital diabetes management tools and earlier this year added CGM-guided insulin dose titration to its offerings. Nemaura’s sugarBEAT, a CE-marked device, offers non-invasive, flexible continuous […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Nemaura Medical

Nemaura Medical secures $6.5M in funding

August 14, 2023 By Sean Whooley

Nemaura ProBeat glucose monitor

Nemaura Medical (Nasdaq:NMRD) announced that it brought in $6.5 million in non-dilutive funding through a clean debt facility. The Loughborough, England-based company said its debt facility features no warrants or convertible elements. It comes from the company’s existing lender. Nemaura Medical did not list an intended use for the added funds. The company develops daily, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Patient Monitoring, Technology Tagged With: Nemaura Medical

Nemaura Medical to offer CGM-guided insulin dose titration care model

March 15, 2023 By Sean Whooley

Nemaura ProBeat glucose monitor

Nemaura Medical (Nasdaq:NMRD) announced today that it now includes insulin under its DuoPack commercial license agreement. Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.” […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Nemaura Medical

Nemaura Medical garners U.S.-based purchase order for glucose sensors

January 27, 2023 By Sean Whooley

Nemaura ProBeat glucose monitor

Nemaura Medical (Nasdaq:NMRD) announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions. HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Nemaura Medical

Nemaura Medical dips on Q1 losses

August 17, 2020 By Sean Whooley

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) shares took a slight hit today on first-quarter results that reflected losses of over $1 million. The Loughborough, England-based continuous glucose monitor maker did not report its revenue numbers for the quarter, having posted losses of $1.1 million, or -5¢ per share for the three months ended June 30, 2020, for a 12.1% […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Nemaura Medical

Nemaura Medical repurposes its CGM to spot coronavirus fevers

April 1, 2020 By Sean Whooley

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. The Loughborough, England-based company said in a news release that its inbuilt temperature sensor is capable of continuously tracking body temperature through the […]

Filed Under: Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: coronavirus, COVID-19, Nemaura Medical

Nemaura Medical enters non-binding agreements for its SugarBeat platform

March 10, 2020 By Sean Whooley

Nemaura Medical (NSDQ:NMRD) announced today that it entered into multiple verbal non-binding agreements for its SugarBeat continuous glucose monitor as it seeks to secure regional and global partnerships. The Loughborough, U.K.–based company expects the agreements to lead to discussions over licensing and collaboration, but can’t guarantee that deals will be struck as planned, or at all, […]

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring Tagged With: Nemaura Medical

Nemaura bids for de novo clearance from FDA for SugarBEAT glucose monitor

July 12, 2019 By Danielle Kirsh

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. “We are pleased to have submitted our De Novo 510(k) application […]

Filed Under: Diabetes, Food & Drug Administration (FDA) Tagged With: Nemaura Medical

Nemaura Medical wins CE Mark for SugarBeat CGM

May 30, 2019 By Danielle Kirsh

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) said yesterday that it won CE Mark approval for its SugarBEAT continuous glucose monitor. The SugarBEAT CGM is a flexible, disposable patch that’s connected to a rechargeable transmitter and Bluetooth-enabled smartphone app, designed to deliver glucose readings at five-minute intervals throughout the day. The company says the device allows users to spend more […]

Filed Under: Diabetes, Regulatory/Compliance Tagged With: Nemaura Medical

Nemaura prices $2.5m offering to support launch of wearable glucose monitor

December 20, 2018 By Sarah Faulkner

Nemaura logo

Nemaura Medical (NSDQ:NMRD) said this week that it priced a public offering of the company’s common stock and warrants, hoping to reel in $2.5 million in proceeds. The offering is slated to close today. Nemaura plans to use the offering’s proceeds to support the launch of its wearable glucose monitor in Europe, as well as the […]

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Nemaura Medical

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS